Online Shop
Abacavir
Aceclofenac
Acyclovir
Adefovir
Alfuzosin
Amiloride
Amlodipine
Amoxycillin
Anastrozole
Atropine
Azathioprine
Azithromycin
Baclofen
Bencyclane
Bicalutamide
Bisacodyl
Bisoprolol
Bosentas
Brimonidine
Butenafine
Calcitriol
Capecitabine
Cefixime
Cefoperazone
Cefotetan
Clindamycin
Clobetasone
Clonidine
Cyclosporine
Cyclosporine
Dacarbazine
Desonide
Dextroamphetamine
Didanosine
Duloxetine
Dutasteride
Efavirenz
Emtricitabine
Estradiol
Etoricoxib
Felodipine
Fenofibrate
Finasteride
Flucloxacillin
Fluvoxamine
Formoterol
Formoterol-Budesonide
Gliclazide
Goserelin
Hepatitis
Hyaluronate
Hydrocortisone
Hydroxyurea
Hypromellose
Indinavir
Insulin
Irinotecan
Isotretinoin
Itopride
Ketoconazole
Lamivudine
Levosalbutamol
Linezolid
Lisinopril
Lopinavir
Mercaptopurine
Mesalazine
Mometasone
Mycophenolate
Nateglinide
Nebivolol
Nelfinavir
Nevirapine
Nitrendipine
Olmesartan
Ondansetron
Ormeloxifene
Ornidazole
Orphenadrine
Oseltamivir
Oxcarbazepine
Oxybutynin
Oxytetracycline
Paracetamol
Paracetamol
Piroxicam
Progestin
Propranolol
Pyrantel
Quetiapine
Rabeprazole
Ranolazine
Risedronate
Rizatriptan
Rosiglitazone
Salbutamol
Saquinavir
Sildenafil
Sorbitol
Sucralfate
Tamsulosin
Telmisartan
Tenofovir
Tobramycin
Torsemide
Venlafaxine
Voriconazole
Warfarin
Zolmitriptan

Bosentas.

Structure

- 62.5 mg - Bosentas;
- 125 mg - Bosentas.

Without a Prescription

Bosentas is prescribed for the treatment of pulmonary arterial hypertension (WHO Group I) in patients with WHO Class III or IV symptoms, to improve exercise ability and decrease the rate of clinical worsening.

Dosage

Bosentas treatment should be initiated at a dose of 62.5 mg for 4 weeks and then increased to the maintenance dose of 125 mg.

Doses above 125 mg did not appear to confer additional benefit sufficient to offset the increased risk of liver injury.

Tablets should be administered morning and evening with or without food.

Treatment should be stopped and re-introduction of Bosentas should not be considered. There is no experience with re-introduction of Bosentas in these circumstances.

If Bosentas is re-introduced Bosentas should be at the starting dose; aminotransferase levels should be checked within 3 days and thereafter according to the recommendations above.

Contraindications

- Hypersensitivity: Bosentas is also contraindicated in patients who are hypersensitive to Bosentas or any component of the medication.
- Glyburide: An increased risk of liver enzyme elevations was observed in patients receiving glyburide concomitantly with Bosentas. Therefore co-administration of glyburide and Bosentas is contraindicated.
- Cyclosporine A: Co-administration of cyclosporine A and Bosentas resulted in markedly increased plasma concentrations of Bosentas. Therefore, concomitant use of Bosentas and cyclosporine A is contraindicated.

Form

Blister pack of 10 tablets

Prescription drugs without a script
Prescription drugs no script
Prescription drugs no prescription
Prescription drugs without a prescription
RX no RX
RX without RX
2004 - 2017